Remdesivir precoz para prevenir la progresión a COVID severa en pacientes ambulatorios

Paula Villares Fernández

Paula Villares Fernández Medicina Interna. Hospital Universitario HM Sanchinarro

Palabras clave: Remdesivir; Pacientes COVID ambulatorios

Abstract

Entre los fármacos que pueden evitar la progresión de la enfermedad por SARS COV-2 se posicionan los antivirales como remdesivir y los anticuerpos monoclonales. En este estudio publicado en NEJM en 2022, en los pacientes no hospitalizados con alto riesgo de progresión de COVID-19, un ciclo de remdesivir de 3 días tuvo un perfil de seguridad aceptable y resultó en un 87% menos de riesgo de hospitalización que placebo.

Among the drugs that can prevent the progression of the SARS COV-2 disease are antivirals such as remdesivir and monoclonal antibodies. In this study published in NEJM in 2022, in outpatients at high risk of COVID-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization than placebo.

Recibido: 01 Junio 2022
Revisión: 13 Junio 2022
Aceptado: 04 Julio 2022

Citas

Vol 386 Nº4, págs. 385-387. 2022. Emily L. Heil, Pharm.D., and Shyam Kottilil, M.D. The Goldilocks Time for Remdesivir — Is Any Indication Just Right? The New England Journal of Medicine.

Vol 386 Nº 11, pág. 1094. 2022. Pierre-Vladimir Ennezat, M.D. Outpatient Remdesivir to Prevent Progression to Severe Covid-19. The New England Journal of Medicine.

Vol 22 Nº 2, págs. 209-221. 2021. Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infectious Diseases. Doi: https://doi.org/10.1016/S1473-3099(21)00485-0

Vol 386 Nº6, págs. 497-511. 2021. The WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 — interim WHO Solidarity trial results. The New England Journal of Medicine.

Vol 383 Nº 19, págs. 1812-1826. 2020. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. The New England Journal of Medicine.

Vol 324 Nº 11, págs. 1048-1057. 2020. Spinner CD, Gottlieb RL, Criner GJ,et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA.

Vol 385 Nº 21, págs. 1941-1950. 2021. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. The New England Journal of Medicine. Doi: https://www.nejm.org/doi/10.1056/NEJMoa2107934